Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CERS | CERUS CORP | 2025-10-28 16:08:22 | 1.5 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CERS | 0001020214 | CERUS CORP | US1570851014 | 254900BIEY9XIDA04Q21 | 680262011 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 1220 CONCORD AVENUE | CONCORD | CA | 94520 | UNITED STATES | US | 9252886000 | 1220 CONCORD AVENUE, CONCORD, CA, 94520 | 1220 CONCORD AVENUE, CONCORD, CA, 94520 | — | Biotechnology | 1991 | — | 254 | https://www.cerus.com | 240,000,000 | 181,248,000 | 191,698,794 | Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. | 2025-10-23 15:25:40 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 240,000,000 | -133,000,000 | -35.6568 | 185,789,815 | 4,507,090 | 2.4862 |
| 2023 | 373,000,000 | -533,000,000 | -58.83 | 181,282,725 | 3,664,853 | 2.0633 |
| 2022 | 906,000,000 | 44,000,000 | 5.1044 | 177,617,872 | 3,896,348 | 2.2429 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Vivek Jayaraman | Chief Operating Officer | 2024 | 548,402 | 60,324 | 872,000 | 0 | 3,142 | 1,483,868 |
| Richard Benjamin | Chief Medical Officer | 2024 | 493,077 | 44,377 | 588,600 | 0 | 3,564 | 1,129,618 |
| William M. Greenman | Chief Executive Officer, President | 2024 | 770,000 | 110,495 | 2,092,800 | 0 | 2,322 | 2,975,617 |
| Kevin D. Green | Chief Financial Officer, Vice President | 2024 | 488,119 | 53,693 | 725,940 | 0 | 1,242 | 1,268,994 |
| Chrystal Jensen | Chief Legal Officer, Secretary, General Counsel | 2024 | 468,530 | 46,384 | 588,600 | 0 | 1,242 | 1,104,756 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 281 |
| 2023 | 288 |
| 2022 | 309 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 201,321,000 | 186,797,000 | 188,315,000 |
| Cost Of Revenue | 80,748,000 | 69,967,000 | 74,954,000 |
| Gross Profit | 99,522,000 | 86,400,000 | 87,094,000 |
| Research And Development Expenses | 58,907,000 | 67,639,000 | 64,107,000 |
| General And Administrative Expenses | 75,891,000 | 75,516,000 | 83,335,000 |
| Operating Expenses | 134,798,000 | 146,883,000 | 147,442,000 |
| Operating Income | -14,225,000 | -30,053,000 | -34,081,000 |
| Net Income | -20,918,000 | -37,489,000 | -42,779,000 |
| Earnings Per Share Basic | -0.11 | -0.21 | -0.24 |
| Earnings Per Share Diluted | -0.11 | -0.21 | -0.24 |
| Weighted Average Shares Outstanding Basic | 184,563,000 | 180,270,000 | 176,545,000 |
| Weighted Average Shares Outstanding Diluted | 184,563,000 | 180,270,000 | 176,545,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 20,266,000 | 11,647,000 | 35,585,000 |
| Marketable Securities Current | 60,186,000 | 54,205,000 | 66,569,000 |
| Accounts Receivable | 29,777,000 | 35,500,000 | 34,426,000 |
| Inventories | 38,150,000 | 39,868,000 | 29,003,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 152,022,000 | 144,441,000 | 170,144,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 7,154,000 | 8,640,000 | 10,969,000 |
| Other Assets Non Current | 16,801,000 | 11,425,000 | 21,378,000 |
| Total Assets Non Current | 7,154,000 | 8,640,000 | 10,969,000 |
| Total Assets | 200,917,000 | 197,748,000 | 218,092,000 |
| Accounts Payable | 21,695,000 | 23,842,000 | 33,002,000 |
| Deferred Revenue | 1,398,000 | 2,002,000 | 589,000 |
| Short Term Debt | 19,297,000 | 20,000,000 | 41,250,000 |
| Other Liabilities Current | 18,943,000 | 19,225,000 | 25,203,000 |
| Total Liabilities Current | 63,608,000 | 67,521,000 | 117,058,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 3,888,000 | 3,236,000 | 3,499,000 |
| Total Liabilities Non Current | 80,413,000 | 76,783,000 | 32,472,000 |
| Total Liabilities | 144,021,000 | 144,304,000 | 149,530,000 |
| Common Stock | 186,000 | 181,000 | 177,000 |
| Retained Earnings | -1,065,528,000 | -1,044,610,000 | -1,007,121,000 |
| Accumulated Other Comprehensive Income | -400,000 | -1,274,000 | -2,787,000 |
| Total Shareholders Equity | 56,145,000 | 52,650,000 | 67,610,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,000,000 | 2,400,000 | 2,500,000 |
| Share Based Compensation Expense | 22,867,000 | 20,271,000 | 24,456,000 |
| Other Non Cash Income Expense | — | 0 | 2,200,000 |
| Change In Accounts Receivable | -5,504,000 | 1,102,000 | 9,200,000 |
| Change In Inventories | -7,030,000 | 14,947,000 | 1,768,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,477,000 | -7,335,000 | -4,905,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 11,359,000 | -43,168,000 | -25,615,000 |
| Purchases Of Marketable Securities | 42,975,000 | 2,486,000 | 29,640,000 |
| Sales Of Marketable Securities | 37,682,000 | 15,707,000 | 40,104,000 |
| Acquisition Of Property Plant And Equipment | 2,837,000 | 4,597,000 | 2,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -8,130,000 | 8,624,000 | 8,464,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | -137,000 | -175,000 | -104,000 |
| Repurchase Of Common Stock | 1,000,000 | 1,000,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 804,000 | 925,000 | 4,084,000 |
| Cash From Financing Activities | 4,964,000 | 10,673,000 | 4,192,000 |
| Change In Cash | 8,002,000 | -23,999,000 | -13,686,000 |
| Cash At End Of Period | 20,266,000 | 11,647,000 | 35,585,000 |
| Income Taxes Paid | 356,000 | 322,000 | 270,000 |
| Interest Paid | 9,295,000 | 9,210,000 | 5,100,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.11 | -0.21 | -0.24 |
| Price To Earnings Ratio | -14 | -10.2857 | -15.2083 |
| Earnings Growth Rate | -47.619 | -12.5 | -25 |
| Price Earnings To Growth Ratio | 0.294 | 0.8229 | 0.6083 |
| Book Value Per Share | 0.3083 | 0.2965 | 0.3884 |
| Price To Book Ratio | 4.9956 | 7.2858 | 9.3986 |
| Ebitda | -9,685,000 | -26,381,000 | -34,178,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 514,000 | 71,000 | 1,261,000 |
| Free Cash Flow | 10,845,000 | -43,239,000 | -26,876,000 |
| Return On Equity | -0.3726 | -0.712 | -0.6327 |
| One Year Beta | 2.0692 | 2.2087 | 1.702 |
| Three Year Beta | 1.8472 | 1.7619 | 1.3131 |
| Five Year Beta | 1.4332 | 1.3819 | 1.2872 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Gregory Dean A. | Director | 2025-08-25 | 25,000 | A | 86,725 |
| BJERKHOLT ERIC | Director | 2025-06-03 | 60,000 | A | 222,133 |
| Shan Hua | Director | 2025-06-03 | 60,000 | A | 132,386 |
| Lucena Ann | Director | 2025-06-03 | 60,000 | A | 172,284 |
| NACHTSHEIM JAMI K | Director | 2025-06-03 | 60,000 | A | 208,362 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STEPHENS INC /AR/ | 2025-09-30 | 156,601 | 98,491 | 1.59 |
| Janney Montgomery Scott LLC | 2025-09-30 | 78,000 | 48,900 | 1.5951 |
| Sumitomo Mitsui Trust Group, Inc. | 2025-09-30 | 9,039,431 | 5,685,177 | 1.59 |
| JGP Global Gestao de Recursos Ltda. | 2025-09-30 | 16,665 | 10,481 | 1.59 |
| SG Americas Securities, LLC | 2025-09-30 | 64,000 | 40,062 | 1.5975 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Fidelity Rutland Square Trust II | 2025-08-31 | Strategic Advisers U.S. Total Stock Fund | FSAKX | 14,500 | 18,995 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 266,124 | 348,622.44 | 0.0004 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 352,592 | 461,895.52 | 0.0004 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 56,998 | 74,667.38 | 0.0004 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 1,046,387 | 1,370,766.97 | 0.0033 |